Strategic addition expands Bioness Medical's platform into non-invasive central neuromodulation and strengthens leadership in neurorehabilitation

战略性收购使Bioness Medical的平台扩展到非侵入性中枢神经调节领域，并巩固了其在神经康复领域的领导地位。

VALENCIA, Calif.

加利福尼亚州瓦伦西亚

,

，

April 9, 2026

2026年4月9日

/PRNewswire/ -- Bioness Medical, Inc. ('Bioness', or the 'Company'), a global leader in functional electrical stimulation (FES) and advanced rehabilitation technologies, today announced the acquisition of the PoNS

/PRNewswire/ -- Bioness Medical, Inc.（“Bioness”或“公司”），作为功能性电刺激（FES）和先进康复技术的全球领导者，今天宣布收购PoNS。

®

®

(Portable Neuromodulation Stimulator) System product line. This strategic addition expands Bioness Medical's capabilities into non-invasive central neuromodulation and reinforces its position as a comprehensive provider of solutions for patients with gait and balance disorders resulting from neurological injury or disease..

（便携式神经调节刺激器）系统产品线。这一战略性扩展使Bioness Medical的能力延伸至非侵入性中枢神经调节领域，并巩固了其作为为因神经损伤或疾病导致步态和平衡障碍患者提供全面解决方案的提供商地位。

For nearly 20 years, Bioness has focused on functional electrical stimulation targeting affected limbs to improve mobility and function following stroke, traumatic brain injury, multiple sclerosis, cerebral palsy, and other neurological conditions. The addition of the PoNS System expands the Company's platform to include non-invasive neuromodulation delivered via the tongue, stimulating cranial nerve pathways to promote neuroplasticity and functional recovery..

近20年来，Bioness专注于针对中风、创伤性脑损伤、多发性硬化症、脑瘫及其他神经系统疾病的功能性电刺激治疗受影响的肢体，以改善运动和功能。PoNS系统的加入扩展了该公司的平台，新增了通过舌头进行的非侵入性神经调节，刺激颅神经通路，促进神经可塑性和功能恢复。

The PoNS System has been studied in patients with chronic neurological conditions, demonstrating improvements in gait and balance when used as part of a supervised rehabilitation program.

PoNS系统已在患有慢性神经系统疾病的患者中进行了研究，结果表明，在有监督的康复计划中使用时，可以改善步态和平衡。

Advancing the Future of Neurorehabilitation

推进神经康复的未来

'PoNS technology represents a differentiated approach to neuromodulation that complements our core FES platform,' said Todd Cushman, Chief Executive Officer of Bioness Medical. 'Bioness has built deep relationships with rehabilitation providers over decades. With PoNS, we expand beyond peripheral stimulation into central neuromodulation—offering clinicians a non-invasive therapy that engages neural pathways involved in balance and gait.

“PoNS技术代表了一种差异化的神经调节方法，是对我们核心FES平台的有力补充，”Bioness Medical首席执行官Todd Cushman表示。“几十年来，Bioness与康复服务提供者建立了深厚的关系。通过PoNS，我们将从外周刺激扩展到中枢神经调节，为临床医生提供一种参与平衡和步态相关神经通路的非侵入性疗法。”

This positions Bioness to deliver more comprehensive, multi-modal rehabilitation solutions to patients.'.

这使 Bioness 能够为患者提供更全面、多模式的康复解决方案。

Expanding a Multi-Modal Therapy Platform

扩展多模式治疗平台

The acquisition brings together complementary technology platforms:

这次收购汇集了互补的技术平台：

Bioness Medical's established portfolio, including L300 Go

Bioness Medical的现有产品组合，包括L300 Go

®

®

, H200

，H200

®

®

Wireless, and Vector

无线、矢量

®

®

Gait & Safety System

步态与安全系统

PoNS

PoNS

®

®

neuromodulation therapy, designed to promote neuroplasticity through non-invasive cranial nerve stimulation via the tongue

神经调节疗法，旨在通过舌头进行非侵入性颅神经刺激来促进神经可塑性。

Together, these technologies enable clinicians to address both peripheral motor activation and central neural network modulation within a unified rehabilitation approach.

这些技术共同使临床医生能够在统一的康复方法中解决外周运动激活和中枢神经网络调节问题。

Strengthening Clinical and Commercial Capabilities

加强临床和商业能力

The acquisition enhances Bioness Medical's research and development capabilities and supports expanded clinical programs, including combination therapy approaches integrating FES and neuromodulation.

此次收购增强了Bioness Medical的研发能力，并支持扩展临床项目，包括整合FES和神经调节的组合疗法。

This acquisition also expands Bioness Medical's addressable market within the rapidly growing neuromodulation and neurorehabilitation sectors, positioning the Company for continued growth across both clinical and commercial channels.

此次收购还扩大了Bioness Medical在快速增长的神经调节和神经康复领域的可覆盖市场，使公司能够在临床和商业渠道中持续增长。

The PoNS System product line marks Bioness Medical's third acquisition since becoming an independent neurorehabilitation company following its acquisition by Accelmed Partners ('Accelmed') on December 31, 2024. The Company continues to expand its portfolio through targeted strategic initiatives and organic innovation..

PoNS系统产品线标志着Bioness Medical自2024年12月31日被Accelmed Partners（“Accelmed”）收购成为一家独立的神经康复公司以来的第三次收购。公司继续通过有针对性的战略举措和有机创新来扩展其产品组合。

About Bioness Medical, Inc.

关于Bioness医疗公司

Bioness Medical is a leading provider of advanced rehabilitation technologies designed to restore mobility, function, and independence. Its portfolio spans functional electrical stimulation, robotic gait training, and neuromodulation, supporting clinicians and healthcare systems worldwide with evidence-based solutions..

Bioness Medical 是一家领先的先进康复技术提供商，致力于恢复患者的行动能力、功能和独立性。其产品组合涵盖功能性电刺激、机器人步态训练和神经调节，为全球的临床医生和医疗系统提供基于证据的解决方案。

SOURCE Bioness Medical, Inc.

来源：Bioness Medical, Inc.

21

21

%

%

more press release views with

更多新闻发布观点与

Request a Demo

请求演示